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CASE PRESENTATIONS
Patient 1
A 49-year-old man developed end-stage renal disease
(ESRD) secondary to polycystic kidney disease. He had
undergone home hemodialysis for the past 8 years, with
dialysis 3 times weekly for 5 hours per session via an ar-
teriovenous (AV) fistula. He received a cadaveric kid-
ney 5 years ago. Delayed graft function was complicated
by cytomegalovirus infection and severe cardiomyopa-
thy, which had not been recognized when he received the
transplant. An echocardiogram after transplantation re-
vealed poor function of his left ventricle (ejection fraction
<20%), and dynamic ultrasonic testing showed poor per-
fusion of his transplanted kidney. Graft loss ensued and
he returned to dialysis 4 years ago. A coronary angiogram
demonstrated normal coronary arteries. He was referred
to the Humber River Regional Hospital for training in
daily nocturnal hemodialysis (DNHD).
Upon presentation he was edematous, had bilateral
pleural effusions, and his jugular venous pressure was
high at the angle of the jaw. His blood pressure was 100/60
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mm Hg and heart rate 100 beats/min. His medications in-
cluded metoprolol, 25 mg twice daily; losartan, 100 mg
daily; erythropoietin, 8000 U twice weekly; phosphate
binders; and vitamins. He weighed 74 kg.
His training in nocturnal hemodialysis took 1 month.
He dialyzed himself at home overnight 6 nights per week
for 8 hours using a Fresenius 2008H machine and Frese-
nius F80 polysulfone dialyzers with a blood flow of 300
mL/min and dialysate flow of 500 mL/min. His dry weight
was decreased by 8 kg to 66 kg, at which point he was
edema-free but hypotensive; the losartan was discontin-
ued. He looked cachectic but his condition started im-
proving rapidly. His appetite improved and his weight
increased progressively; he gained 26 kg over the fol-
lowing 32 months. His body fat, measured by single-
frequency bioelectrical impedance (BIA), increased by
15.6 kg and his lean body mass by 10.8 kg over the
same period. His extracellular fluid (ECF) volume, also
measured by BIA, decreased from 29.0 to 19.2 kg
within 1 month and remained stable. The extracellular-to-
intracellular fluid (ECF/ICF) ratio decreased from 1.19
to 0.84 within 1 month after training and continued to
decrease gradually to 0.64 after 32 months and remained
stable. The serum albumin, 2.7 g/dL at presentation, in-
creased initially to 3.0 g/dL within 1 month as a result of
the initial fluid removal and then increased gradually to
4.0 g/dL 1 year later and remained stable.
The erythropoietin (Epo) dose was 8000 U/week sub-
cutaneously prior to transplantation; 16,000 U/week at
the end of his training; and 30,000 U/week 6 months af-
ter training. The dose remained unchanged for 1 year.
Then the Epo requirements started decreasing gradually
and the medication was finally discontinued 2.5 years
after his training. His hemoglobin, 12.5 g/dL prior to
the transplantation and 9.7 g/dL at the end of dialy-
sis training, stabilized at an average of 13 g/dL during
the first 2 years. His most recent hemoglobin mea-
surement, 20 months after discontinuation of Epo, was
16.5 g/dL.
After the first few months of training, his exercise tol-
erance improved significantly, and he continues to work
full time. His ventricular function improved 6 months af-
ter his training and normalized 1 year later. He is currently
awaiting another kidney transplant.
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Patient 2
A 44-year-old man was referred to the Humber River
Regional Hospital 5 years ago for training in DNHD. He
had ESRD as a result of IgA nephropathy. He started on
in-center hemodialysis 15 years ago and received a cadav-
eric renal transplant 2 years later, but the graft was lost to
rejection. He was again started on in-center hemodialysis
8 years ago. Despite the use of calcium-based phosphate
binders, phosphate control was poor. His predialysis
phosphate level ranged from 6.3 to 9.6 mg/dL (2.1 to 3.2
mmol/L). Over time he developed tumoral deposits of
extra-osseous calcification in his hands, feet, and right
shoulder. The deposits became so large that they im-
paired function and caused localized tenderness, recur-
rent episodes of cellulitis, and ulceration of the overlying
skin. He was unable to wear shoes or to continue work-
ing. Radiologic investigation confirmed the presence of
large tumoral calcific deposits in multiple areas as well as
diffuse vascular calcifications.
The patient completed his training in daily nocturnal
hemodialysis in 2 to 3 months. He underwent dialysis 6
nights per week over an 8-hour period per session. A
high-flux, large-surface-area, biocompatible membrane
was used (Fresenius F80 polysulfone dialyzers) with a
blood and dialysate flow rate of 300 mL/min each. Cal-
cium, in the form of a powder, was added to the dialysate
(3.0 to 4.2 mEq/L; 1.50 to 2.10 mmol/L) to maintain a to-
tal calcium blood level at the upper limit of normal. The
patient’s predialysis serum phosphate level fell rapidly
upon initiation of DNHD and stayed normal through-
out the course, allowing him to discontinue taking oral
calcium carbonate while liberalizing his diet. Because of
high phosphate clearance with DNHD, the patient started
adding sodium phosphate (Fleet enema) to the dialysate
bath (acid concentrate) to avoid postdialysis hypophos-
phatemia. On this regimen, the plasma parathyroid hor-
mone (PTH) level declined dramatically from 1810 to 162
pg/mL (190 to 17 pmol/L) by the 4th month, as did alka-
line phosphatase, from 211 to 88 U/L. Despite his mildly
elevated serum calcium levels, which resulted from the
high dialysate calcium, the patient’s Ca × PO4 product
fell below 55 mg2/dL2 (4.4 mmol2/L2) and remained be-
low this threshold throughout his course.
The size of the calcium deposits started decreasing at
about 2 to 3 months after the initiation of DNHD, and dis-
solution of these lesions was almost complete at 9 months,
as shown by radiologic evaluation, with no recurrence.
No evidence suggested that the vascular calcifications de-
creased appreciably throughout this period. The patient
felt very well on DNHD. Within a few months, he was
able to wear regular shoes and participate in social activ-
ities. Over this same time, his need for antihypertensive
medications decreased, and within 12 months his Epo
requirement fell to zero. Two years ago, he successfully
underwent a second cadaveric renal transplantation.
Patient 3
A 27-year-old woman was diagnosed with IgA
nephropathy and progressed to ESRD. She began in-
center hemodialysis using an AV fistula 3 years ago. She
was transferred to a self-care dialysis unit in Toronto,
where she was dialyzed for 4 hours 3 times weekly.
Although she took antihypertensive agents (atenolol,
100 mg daily; amlodipine, 10 mg daily; ramipril, 5 mg
daily; and clonidine, 0.1 mg twice daily), her hyperten-
sion was poorly controlled (blood pressure > 160/95 mm
Hg). She complained of headaches and could not tolerate
a decrease in her dry weight. She was trained in DNHD
2 years ago. After the conversion, her dry weight was de-
creased progressively from 53 to 49 kg within 1 month
despite the previous lack of evidence of increased ECF
volume. Her blood pressure control improved but she
continued to need most of the antihypertensives. Despite
resistance she was convinced to accept a decrease in her
dry weight further to 47 kg. Her blood pressure normal-
ized and all medications were discontinued but only 2 to 5
months after completion of her training. As a result of im-
proving appetite, however, her dry weight was increased
progressively from 47.0 to 50.5 kg over 6 months. The
ECF volume, measured using single-frequency BIA, de-
creased from 14.3 kg prior to the conversion to DHND to
12.4 kg one month later, and further to 10.2 kg 8 months
after the conversion while her dry weight was increasing.
The ECF/ICF ratio measured by BIA decreased similarly
from 0.97 to 0.80 and 0.66 before, 1, and 8 months after
the conversion. Her hemoglobin, 10.5 g/dL at the time
of the conversion, increased to 14.1 g/dL after the initial
decrease in the dry weight and remained stable over the
following 2 years at 13.4 ± 1.2 g/dL. The dose of Epo of
6000 U/week subcutaneously at the time of the training
was gradually discontinued 8 months after the conver-
sion. She has not taken Epo for 13 months.
DISCUSSION
DR. ANDREAS PIERRATOS (Head, Home Dialysis Unit,
Humber River Regional Hospital, and Associate Profes-
sor of Medicine, University of Toronto, Toronto, Canada):
Daily nocturnal home hemodialysis (DNHD) com-
bines the advantages of home hemodialysis, short daily
hemodialysis (SDHD) and long intermittent hemodial-
ysis. Daily nocturnal home hemodialysis was started in
Toronto in 1994 by Dr. Robert Uldall with the help of a
grant from the Ministry of Health, province of Ontario,
Canada [abstract; Uldall PR et al, J Am Soc Nephrol
5:428, 1994]. It is done at home by the patient or a family
member at night during sleep for an average of 8 hours
usually 6 nights a week [1]. I first will review briefly the
history and some data on home, long intermittent, and
short daily hemodialysis before discussing daily nocturnal
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hemodialysis, a new and provocative topic in the dialysis
world.
Home hemodialysis was first used by Nose´ in Japan
in 1963 [2]. Home hemodialysis utilization, high in the
1970s, has since declined significantly worldwide. Some
of the reasons include the introduction of continuous am-
bulatory peritoneal dialysis (CAPD), an increase in the
number of dialysis units in developed countries, finan-
cial constraints, and the increasing number of patients
with significant co-morbidities who are unable to per-
form their own dialysis [2]. Although some of the su-
perior results of home hemodialysis might be related
to the selection of stable patients, a retrospective anal-
ysis of United States Renal Data System (USRDS) data
suggested a decreased mortality risk ratio for home
hemodialysis patients after adjustment for age, gender,
race, and co-morbidities (RR 0.58, P = 0.03) [3]. Better
quality of life, independence, and vocational rehabilita-
tion have been some of the benefits of home hemodialy-
sis [4]. The decline in utilization of CAPD, overcrowding
of dialysis units, shortage of nurses, and lower cost of
home hemodialysis have rekindled the interest in home
hemodialysis.
The use of long, usually 8 hours, dialysis was neces-
sary during the early years because inefficient dialyzers
were used. The Dialysis Unit in Tassin, France is the best
known unit that has continued using the 8-hour, thrice-
weekly schedule, now for more than 30 years [5]. Patient
survival has been high, 75% over 10 years. Although the
early patient cohorts had fewer comorbidities, the sur-
vival rate of the later cohorts (54% over 5 years) was
still twice as high as those reported by USRDS. Blood
pressure control has been excellent even without the use
of antihypertensive medications, as a result of a progres-
sive decrease in the postdialysis weight (dry weight) and
low-salt diet. Interestingly, despite good blood pressure
control, lack of regression of left-ventricular hypertrophy
(LVH) has been reported [6]. Also, despite increased mid-
dle molecule clearance by long hemodialysis [7], dialysis-
related amyloidosis has not been avoided [8]. The lack
of use of modern technology and Epo might be rele-
vant. Phosphate control is improved on long intermittent
hemodialysis, but phosphate binders are needed for the
majority of the patients. Resurgence of the popularity
of long intermittent hemodialysis thrice weekly or ev-
ery other day, in-center or at home at night, has recently
provided a cost-effective way of improving dialysis ef-
ficacy within the limits of current reimbursement rates
[abstract; Kurella M et al, J Am Soc Nephrol 13:410A,
2002].
Short daily hemodialysis was first described by De-
Palma in 1969 [9]. Despite patient improvement, early
successful efforts were abandoned because of the finan-
cial burden [10]. Most of the literature on SDHD has
originated in Italy over the last 15 years [11, 12], mainly
from Buoncristiani’s group. A recent resurgence of in-
terest led to publications by several groups in Europe as
well as North and South America [13–17]. Despite some
variations, the dialysis regimen comprises 2.0 to 2.5 hours
of high-efficiency dialysis 6 days per week, either in cen-
ter or at home. The rationale of SDHD is that it provides
enhanced hemodynamic stability and increases solute re-
moval by delivering dialysis when the plasma-to-dialysate
gradient is highest. Urea standard Kt/V (stdKt/V), a new
yardstick of dialysis dose proposed by Gotch in 1998 [18],
is used to compare the dose offered by dissimilar dial-
ysis regimens. The stdKt/V is the same for all dialysis
methods characterized by the same midweek predialysis
blood urea nitrogen (BUN). Conventional hemodialy-
sis (CHD) and CAPD, with a weekly stdKt/V of 2 (as
per DOQI guidelines), have the same outcomes, so it is
assumed that this observation applies to other modal-
ities with similar stdKt/V. This conclusion needs to be
experimentally confirmed, however. An SDHD of sim-
ilar length per week with CHD offers a higher stdKt/V
of about 3.5 and therefore can potentially explain better
outcomes [19]. Larger molecule removal is also enhanced
by daily hemodialysis [7, 20–22]. Short daily hemofiltra-
tion, introduced recently, increases the large molecule
removal further, despite a lower removal rate of smaller
molecules [23].
Several studies have shown significant improvement of
quality of life after conversion to SDHD [13, 24]. Blood
pressure control improves, and the dose of antihyperten-
sive agents can be decreased by more than 50% [15]. Also
SDHD leads to regression of LVH [25]. Both blood pres-
sure control as well as regression of LVH have been asso-
ciated with a decrease in the ECF volume [25] [abstract;
Nesrallah G et al, J Am Soc Nephrol 12:273A, 2001].
SDHD increases phosphate removal but improving ap-
petite and increased phosphate intake help maintain the
serum phosphate level [abstract; Traeger J et al, J Am
Soc Nephrol 13:410A–411A, 2002]; the dose of phosphate
binders does not change consistently [13]. Nutritional pa-
rameters improve on SDHD, including serum albumin,
pre-albumin, protein intake, and body weight, although
not all studies have reported these findings [26]. Hemat-
ocrit improved in most studies despite a decrease in the
dose of Epo by as much as 40%; some studies did not con-
firm this observation, probably because of iron deficiency
or inadequate length of follow-up [15, 27].
Let me now turn to my major theme, that is, that
daily nocturnal hemodialyis is the best form of chronic
hemodialysis. Quality-of-life instruments showed signif-
icant improvement in the quality of life, including the
sickness impact profile, Beck Depression Index, and 3 pa-
rameters of SF-36 [24] [abstract; Brissenden JE et al, J Am
Soc Nephrol 9:168A, 1998]. Uremic and dialysis-related
symptoms disappear, usually within the first month, but
full recovery is not complete for almost 1 year. The level
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of energy improves and leads to social and vocational
rehabilitation.
Patient or family member training is performed while
the patient is undergoing CHD. Training lasts for 2 to 8
weeks, usually 5 weeks, followed by 3 dialysis sessions
overnight in the training center. The remarkable stabil-
ity offered by DNHD allows patients with hemodynamic
instability on CHD to be dialyzed at home. Excluding pa-
tients who cannot receive heparin, no medical contraindi-
cation to this modality has been encountered. I should
stress this point since traditionally only healthier patients
were selected for home hemodialysis. Patients with se-
vere congestive heart failure, systemic hypotension, coro-
nary artery disease, ascites, hemodynamic instability, or
systemic hypotension benefit significantly from DNHD.
Over 9 years, 90 patients were trained at the Humber
River Regional Hospital in Toronto. These patients were
aged 49 ± 11 years; 57 were males, 33 females. Of the 88,
9 died, 10 left the program, 16 had renal transplantation,
48 currently dialyze every night, and 5 dialyze every other
night because they are awaiting further funding so that
they can be converted to the every night treatment. The
average time in the program was 30 ± 27 months, and the
total experience is 230 patient-years. The longest period
in the program is 9 years. Approximately 90 patients use
DNHD in Toronto.
Technique
Daily nocturnal home hemodialysis can be done using
conventional hemodialysis machines. Blood and dialysate
flows vary, with an average blood flow of 250 mL/min
and a dialysate flow of 300 mL/min. Dialysate flows as
low as 100 mL/min or higher than 500 mL/min have been
used [1]. No sodium ramping or ultrafiltration profiling
is necessary. The presence of a dialysis partner is not
required. When compared to CHD, the dialysate com-
position of DNHD contains a lower bicarbonate level
(average 32 mEq/L), a higher calcium level (average 3.2
mEq/L, 1.6 mmol/L), and might include sodium phos-
phate (see later). Use of ultrapure dialysate is desirable,
but the current data have been collected by using water
compliant with the Association for the Advancement of
Medical Instrumentation (AAMI) guidelines [28]. Hep-
arin use is similar to that for conventional hemodialysis.
Central venous catheters, fistulas, and grafts have been
used as accesses. Safety devices preventing air embolism
or disconnection of the catheters are mandatory [1].
Moisture sensors taped onto the needle sites provide
warning in cases of bleeding or needle dislodgement.
A “single-needle system” provides adequate blood flow
(200 mL/min) and requires the same number of cannula-
tions per week as does conventional hemodialysis. It rep-
resents the preferred and safest configuration. The use
of the same puncture hole (buttonhole) technique in fis-
tulas is optional but provides easier, more predictable,
and less painful cannulation [29]. “Live” remote moni-
toring during dialysis using a telephone or internet con-
nection can provide extra safety and psychologic support
and can help with patient compliance, but at this point
it is not considered mandatory [30, 31]. The internet has
allowed cost-efficient use of remote monitoring. It is ex-
pected that improvement in technology with inclusion of
biologic monitoring (blood pressure, heart rate, oximetry,
etc.) will increase the value of “live” remote monitoring.
Refrigeration of dialyzers at the home of the patient, and
their delivery to the dialysis center only once weekly, al-
lows successful dialyzer reprocessing, if desired [32].
The dialysis dose on DNHD is high. The Kt/V calcu-
lated using dialysate collection was 0.99 ± 0.3 using a
dialysate flow of 100 mL/min [1]. Using higher dialysate
flow, single-pool Kt/V (spKt/V) usually yields a Kt/V of
about 2 [33]. The weekly standard Kt/V as defined by
Gotch is about 5 [34]. Therefore DNHD is particularly
well-suited for large patients. Due to the long total dura-
tion of dialysis, larger molecule removal is high. This was
shown by simulated computer models [7, 35] and by mea-
suring weekly dialysate b 2-microglobulin removal. The
amount of b 2-microglobulin removed increased fourfold
after conversion from CHD to DNHD (127 ± 48 mg ver-
sus 585 ± 309 mg, P < 0.001). Serum b 2-microglobulin
levels decreased over time from 27.2 ± 11.7 mg/dL at ini-
tiation of DNHD, to 13.7 ± 4.4 mg/dL by 9 months [36]. It
is possible that the decrease in b 2-microglobulin produc-
tion is partially responsible, as there is variability in the
serum levels while on the same regimen. To this point, no
evidence of “deficiency syndromes” caused by excessive
dialysis has surfaced.
Phosphate removal by conventional hemodialysis is
suboptimal, and an elevated calcium x phosphorus prod-
uct is associated with increased patient mortality rates
[37]. Length of dialysis is a major determinant of phos-
phate removal. Weekly phosphate removal by DNHD
is twice that of CHD (4.8 ± 1.7 g versus 2.2 ± 0.6 g)
[38]. All patients stop taking phosphate binders within
1 week of the initiation of the treatment and are on an
unrestricted phosphate diet. In fact, more than 50% of
patients require the addition of sodium phosphate into
the dialysate. This is usually achieved by the patient
adding sodium phosphate into either the “acid”- (low
pH prevents precipitation with calcium) or bicarbonate-
containing concentrate. We use Fleet enema as a source
of sodium phosphate. Serum phosphate was normal pre-
and postdialysis at 3.6 ± 0.6 mg/dL (1.2 ± 0.21 mmol/L)
and 2.6 ± 0.3 mg/dL (0.8 ± 0.1 mmol/L), respectively
[abstract; Pierratos A et al, J Am Soc Nephrol 12:274A,
2001]. The control of hyperphosphatemia unique to this
method provides clinicians with the opportunity to pre-
vent or correct some of the major complications of
ESRD [37]. The effect of phosphate control is evident in
Nephrology Forum: Nocturnal home hemodialysis 1979
Fig. 1. Tumoral calcification prior to and
after 9 months of daily nocturnal home
hemodialysis. (Reprinted from [39] with per-
mission from the National Kidney Founda-
tion.)
Patient 2. The massive extra-osseous calcifications in this
patient dissolved despite the use of high-dialysate cal-
cium (Fig. 1) [39]. Patients undergoing DNHD do not
use calcium-containing phosphate binders and have low
gastrointestinal calcium absorption, so they can easily
be in negative calcium balance due to the removal of
ultrafilterable calcium during ultrafiltration. Therefore
high-dialysate calcium is necessary for them to maintain
the desired calcium balance. The bone density of sev-
eral patients decreased on DNHD but improved when
dialysate calcium was increased. Bone densitometry ev-
ery 6 to 12 months is strongly recommended. The aver-
age dialysate calcium has been 3.26 ± 0.20 mEq/L (1.63
± 0.10 mmol/L). PTH was suppressed from 580 ± 590
pg/mL to 228 ± 295 pg/mL (P = 0.007) within 6 months
by increasing dialysate calcium as necessary. Of the 15
bone biopsies from patients who underwent DNHD for
an average of 32 months, 9 showed low bone turnover, 5
had osteitis fibrosa (pre-existing), and 1 had normal bone
histology [abstract; Pierratos A et al, J Am Soc Nephrol
12:274A, 2001]. Dialysate calcium concentration needed
to be increased during the phase of bone repair in patients
with hyperparathyroidism or during pregnancy in one pa-
tient. The high prevalence of low bone turnover might be
related to the use of high dialysate calcium. More stud-
ies are needed to establish criteria for the adjustment of
dialysate calcium levels.
Improvement in blood pressure control during DNHD
occurs early in the treatment. A decrease in “dry weight,”
well tolerated, is followed by a progressive decrease in
the blood pressure and an associated reduction in the
dose of antihypertensive medication. Systolic, diastolic,
and pulse pressure decreased, from 145 ± 20 mm Hg to
122 ± 13 mm Hg, P < 0.001; from 84 ± 15 mm Hg to 74 ±
12 mm Hg, P < 0.02; and from 61 ± 12 mm Hg to 49 ±
12 mm Hg, P < 0.002, respectively [33]. The number
of antihypertensive agents decreased from on average
1.8 to 0.3 medications (P < 0.001). A small dose of
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atenolol was used intermittently in 20% to 30% of the
patients as the only medication [33]. Patient 3 is an ex-
ample of such a response. The postdialysis ECF volume
measured by single-frequency BIA did not change after
1 year in patients undergoing DNHD [33]. Therefore it
seems that a decrease in ECF volume is not the only
mechanism responsible for the decrease in blood pres-
sure. Chan et al, using echocardiography, reported a de-
crease in total peripheral resistance in 15 patients from
2073 ± 1097 to 1471 ± 900 dyne.sec.cm−5 (P = 0.05)
2 months after conventional hemodialysis was con-
verted to DNHD [40]. Endothelium-dependent vasodi-
lation also improved, as measured by the brachial artery
diameter pre- and posthypoxemia, and endothelium-
independent vasodilation improved as well, as measured
in response to nitroglycerine. The involvement of addi-
tional mechanisms beyond ECF volume decrease in the
control of blood pressure in long hemodialysis also was
suggested by other investigators [41]. Decreased heart
rate variability (defined as the standard deviation of
the RR intervals), which indicates increased sympathetic
tone and is associated with increased mortality rates, has
been observed in patients with ESRD [42]. Heart rate
variability was measured during sleep in 9 patients under-
going CHD, after their conversion to DNHD, and in 10
controls. The ratio of high frequency/low frequency spec-
tral power indicated significantly greater sympathetic
modulation of heart rate variability in patients under-
going CHD; normalization of this ratio occurred after
conversion to DNHD [43]. Daily nocturnal hemodialysis
can improve cardiac function. Six patients with impaired
cardiac function were followed before and 3.2 ± 2.1 years
after conversion to DNHD. Cardiac function improved,
with the left-ventricular ejection fraction rising from 28%
± 12% to 41% ± 18%, as measured by radionucleotide
angiography [44]. Patient 1 is an example of this improve-
ment. His transplanted kidney failed, mainly because of
hypoperfusion as a result of cardiac failure. Gradually his
left-ventricular function improved and he became eligi-
ble for another kidney transplant. We have seen such dra-
matic improvement in other of our patients. Thus, DNHD
is the treatment of choice for severe cardiac dysfunction.
Hyperhomocysteinemia, an independent risk factor for
atherosclerotic vascular disease, is present in more than
85% of hemodialysis patients and does not improve on
treatment with vitamin supplements or high-flux dialy-
sis. Predialysis plasma total homocysteine levels in 23 pa-
tients undergoing DNHD were compared with those in
31 patients undergoing conventional hemodialysis [45].
DNHD was associated with 6.0 lM lower mean homo-
cysteine levels (P = 0.001). The clinical significance of
this observation remains to be determined.
Patients undergoing DNHD have no dietary restric-
tions. Despite the increased frequency and length of dial-
ysis and increased amino acid losses in the dialysate [46],
serum levels of essential (EAA), nonessential (NEAA),
and branched amino acids increased after conversion
to DNHD [47]. However, abnormalities in the ratios of
EAA/NEAA, valine/glycine, and tyrosine/phenylalanine
persisted. The impact on nitrogen balance of amino-acid
loss into the dialysate was examined by measuring total-
body nitrogen in a cohort of 24 patients. Measurements
every 6 to 24 months, over an average of 15.7 months, were
assessed by in vivo neutron activation analysis. Total-
body nitrogen increased nonsignificantly, providing as-
surance that the patients were not in negative nitrogen
balance. Body weight in 48 patients, followed for an aver-
age of 24.5 months, increased from 77.8 ± 18.37 kg to
80.3 ± 18.4 kg (P = 0.014). Serum albumin averaged
4.0 ± 0.4 g/L. Patient 1 gained an exceptional amount
of weight, 29 kg. Most investigators have reported that
their patients have had increased appetite and weight
gain [48] [abstract; Williams AW et al, J Am Soc Nephrol
10:270A, 1999]. The nutritional aspects of DNHD need
further study.
Sleep disorders are prevalent in the dialysis population,
and they correlate with patient mortality [49]. The effect
of DNHD on sleep patterns was examined in the first 14
patients enrolled in the nocturnal hemodialysis project
in Toronto prior to and after their conversion from CHD
to DNHD [50]. Of 14 patients, 7 had sleep apnea, de-
fined as an apnea-hypopnea index (AHI) of more than
15 episodes per hour. The AHI in these patients fell from
46 ± 19 per hour to 9 ± 9 per hour (P = 0.006) and was
accompanied by increases in the minimal oxygen satura-
tion from 89.2% ± 1.8% to 94.1% ± 1.6% (P = 0.005).
The periodic limb movements (PLMs) did not improve
on DNHD. In a separate study, both the Epworth Sleepi-
ness Scale (ESS) and the Multiple Sleep Latency Test
(MSLT) were used to examine the effect of DNHD on
daytime sleepiness on the first 24 patients enrolled in the
project [51]. Of the 24 patients, 54% were found to be
“somnolent,” and PLMs were more common in the som-
nolent group. The PLMs correlated with daytime sleepi-
ness. Altogether, DNHD did not improve the daytime
sleepiness.
Anemia is reported to improve on DNHD [33, 52,
53]. In 28 patients followed for an average of 3.4 years,
hemoglobin increased from 10.7 ± 1.3 g/dL to 11.8 ±
1.6 g/dL, and Epo dose decreased from 10,372 ± 8065
U/week to 8090 ± 6832 U/week. In a control group of 13
self-care patients, hemoglobin remained unchanged, as
did the Epo dose over the follow-up period of 2.8 years
[33]. Improvement in anemia was evident in each of the
patients discussed today who, after an initial period on
DNHD, did not need Epo. The effect of DNHD on Epo
requirements is highly variable and often delayed until
after the first year on the treatment. Of the patients cur-
rently enrolled in the DNHD program of the Humber
River Regional Hospital, 26% are not receiving Epo, and
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Fig. 2. Cumulative patient survival on daily nocturnal home hemodial-
ysis at Humber River Regional Hospital. DNHD, daily nocturnal
hemodialysis.
in some patients, iron administration is being withheld to
avoid a further increase in hemoglobin.
Data on mortality statistics have not been published.
The current relatively small number of patients and lack
of availability of pooled data from many centers pre-
cludes meaningful analysis. Patient survival at the Hum-
ber River Regional Hospital is 81% over 5 years (83
patients) (Fig. 2). I should stress that despite the lower
mean age of the patients, they often were referred for
treatment because of the presence of significant comor-
bidities and arguably are representative of the dialysis
population.
Cost
We examined the cost of DNHD in a prospective, con-
trolled study [53]. We followed for 1 year 23 patients on
conventional hemodialysis who were matched for willing-
ness and ability to be trained on DNHD, as well as 33 pa-
tients already on DNHD. The total cost of care, including
direct cost of dialysis, capital, staffing, medications, hos-
pitalization, “overhead,” and physician reimbursement,
was captured prospectively. The direct cost of providing
hemodialysis was higher with DNHD, as was the capital
cost. Staffing and overhead costs were higher on CHD,
and we noted trends toward a lower cost of medications
and hospitalizations on DNHD. The weekly mean cost for
total health care delivery was 20% less for DNHD, with
a projected mean annual savings of more than $10,000
CAD (P = 0.006). Mohr et al obtained similar results
in a retrospective study [24]. We also performed a cost
utility study [54]. Utility scores were generated using the
standard gamble (SG) technique. Mean SG scores were
0.77 ± 0.23 for DHND and 0.53 ± 0.35 for conventional
hemodialysis (P = 0.03), favoring DNHD. The cost-utility
was $71,443 CAD/QALY (Quality Adjusted Life Year)
for DNHD, and $125,845 CAD/QALY for conventional
hemodialysis. This study demonstrated that daily home
nocturnal hemodialysis offers improved quality at lower
cost.
Short-term assessment
Despite the advantages of DNHD, its current utiliza-
tion is quite small. The main obstacle is the increased
direct cost of providing hemodialysis daily. In most coun-
tries, hemodialysis is reimbursed for three sessions per
week. The potential savings I have described might not
benefit the dialysis provider who incurs the cost of dial-
ysis. Another obstacle is the lack of infrastructure for
patient training and follow-up. Most nephrologists and
nurses have no experience with home hemodialysis. The
third obstacle is related to the relatively low rate of pa-
tient eligibility for training. While there is no medical con-
traindication for DNHD, the ability of patients to learn
using the currently available hemodialysis machines is
variable, as is the availability of a family member to serve
as a helper. Eligibility is currently estimated at 15% to
20% of patients. The dialysis industry recently has shown
some interest in creating or modifying existing dialysis
machines to facilitate patient training [55]. Education of
physicians, nurses, and patients will have a significant im-
pact on patient recruitment. More studies are needed to
convince the payers that the clinical and financial benefits
of the daily regimens are significant; then the reimburse-
ment model can be restructured and appropriate reim-
bursement provided. The recently announced initiative
by the National Institutes of Health and the Centers for
Medicare and Medicaid Services regarding a randomized
controlled pilot study comparing conventional hemodial-
ysis with one of the daily forms of hemodialysis will likely
have a significant impact on providing the necessary data
or will lead to full-scale randomized control studies [56].
The recently published ADEMEX study [57] has
shown that an increase in the peritoneal dose of CAPD
did not decrease patient mortality rates. Similarly, the
HEMO study [58] concluded that overall patient mor-
tality rates do not decrease if one increases Kt/V from
1.32 ± 0.09 to 1.71 ± 0.11 when using the three-times-
a-week hemodialysis regimen or using high-flux dialyz-
ers. The exceptions included women who benefited from
a higher dialysis dose and patients on dialysis for more
than 3.7 years who benefited from the use of high-flux di-
alyzers. The latter suggests a beneficial effect from larger
molecule removal in patients who have lost their residual
renal function. These studies should prompt us to explore
alternative dialysis regimes and technologies. Increased
dialysis frequency and/or length are the next logical steps
to be investigated.
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No adequate studies have compared DNHD to SDHD
or long intermittent hemodialysis. The results of a
prospective nonrandomized study comparing short daily
home hemodialysis to DNHD, including 11 and 12 pa-
tients in each group respectively as well as a group of
patients on conventional hemodialysis dialyzed in hos-
pital, were recently published [59]. The small number
of patients involved preclude final conclusions, but the
study suggested that both forms of daily hemodialysis
are better than conventional hemodialysis. Obviously,
large multicenter studies are needed to compare rigor-
ously these so-called “intensive hemodialysis” regimens.
Furthermore, there is recent interest in the use of daily
short hemofiltration at home [60] and daily hemodiafil-
tration in-center [61]. Daily hemofiltration is less efficient
in small-molecule removal but more efficient in larger-
molecule removal [23]. Therefore the adequate dose of
daily hemofiltration needs to be established. Although
the use of in-center hemodiafiltration is becoming more
affordable and represents an attractive option [62], there
is no experience with home hemodiafiltration.
In the current era of inadequate reimbursement for
daily dialysis regimens, their use is expected to be lim-
ited unless changes in the reimbursement structure take
place [63]. In the in-center facilities, one can envisage
the use of short daily hemodialysis/hemo(dia)filtration
limited to patients with significant comorbidities. Long
overnight hemodialysis, three times a week or every other
night for patients who are willing to sleep in the hospital,
represents an attractive affordable option and is increas-
ing in popularity [abstract; Kurella M et al, J Am Soc
Nephrol 410A, 2002]. At home, the use of long, every-
other-night hemodialysis represents the most attractive
solution at present, as it provides significant advantages
with a minimal increase in cost. When adequate funding
is secured for daily treatments, the use of daily regimens
in center will increase, especially for patients with hemo-
dynamic instability, hypertension, malnutrition, or other
comorbidities as well as for patients who are eager to im-
prove their quality of life. At home, short daily hemodial-
ysis/hemofiltration and DNHD will be utilized, reflecting
the preference of the patients and the dialysis center’s
experience and bias. The use of long intermittent
hemodialysis, daily hemodialysis, and daily nocturnal
hemodialysis will increase the use of home hemodialysis.
This, in concert with the encouragement for higher uti-
lization of CAPD, at least as initial treatment in suit-
able patients, will help decrease dependence on in-center
hemodialysis [64].
In short, daily nocturnal home hemodialysis is a highly
promising treatment for ESRD, a breakthrough in the
opinion of the patients and health care workers who have
experienced its impact. Along with short daily hemodial-
ysis or hemofiltration and long intermittent hemodial-
ysis, DNHD will revitalize home dialysis and therefore
provide solutions to the problems of staff shortages and
overcrowding of dialysis units. Studies that will lead to the
appropriate reimbursement of these methods are needed.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Division of Nephrol-
ogy, Tufts-New England Medical Center, Boston, Mas-
sachusetts): Could you tell us what other institutions in the
United States and Canada are doing comparable work?
DR. PIERRATOS: There is no comprehensive list of
centers practicing daily nocturnal hemodialysis. A daily
hemodialysis registry covering initially the North Amer-
ican and later the international experience is at an ad-
vanced stage of development. Three hospitals in Toronto
have a total of about 110 patients on nocturnal hemodial-
ysis. Other Canadian centers are in London (Ontario),
Alberta, and British Columbia, with a total of about 140
patients in Canada. The longest experience in the United
States is in Lynchburg, Virginia, and Saratoga Springs,
New York, with other centers in Kansas City, St. Louis,
Columbia (Missouri), Cleveland (Ohio), Winston-Salem
(North Carolina), and Sacramento (California), with a to-
tal of about 200 patients. Many centers practice SDHD.
Centers using quotidian nocturnal hemodialysis exist in
Australia, the Netherlands, Germany, Sweden, and other
countries.
DR. HARRINGTON: You stated that 26% of your pa-
tients on home nocturnal hemodialysis were able to stop
taking Epo. Do you know what the serum Epo levels
were in those patients? Assuming for a moment that the
Epo level remained low, how do you account for that
observation?
DR. PIERRATOS: We do not have serum Epo levels.
Except for reversal of the hyporesponsiveness of the
bone marrow to Epo and improvement of red cell sur-
vival related to better uremic control, the intriguing role
of insulin-like growth factors (IGFs) on Epo needs to
be explored. Insulin-like growth factor can stimulate the
erythroid cell progenitors [65]. Patients with high serum
levels of IGF, and specifically high IGF-binding protein
1, have higher hematocrit levels [66]. One can speculate
that the improvement of anemia in some of these patients
is partially due to changes in serum IGF levels or IGF-
binding protein. It is also possible that the discontinuation
of treatment with angiotensin-converting enzyme (ACE)
inhibitors because of better control of blood pressure con-
tributes to the increased hematocrit in some patients [67].
This is a fertile area for research.
DR. JAMES STROM (Division of Nephrology, Caritas
St. Elizabeth’s Medical Center, Boston, Massachusetts): I
think most nephrologists would like to see this procedure
available for their patients. How does the direct cost of
the supplies, dialyzers, etc., for six treatments per week
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compare with the United States reimbursement for three
treatments per week (approximately $400)?
DR. PIERRATOS: Most of the dialysis units find the cur-
rent reimbursement of 3 dialysis treatments per week
inadequate. Mohr et al calculated the weekly cost of
nocturnal hemodialysis in the United States at $544, in-
cluding remote monitoring and single-use dialyzers, and
$413 without these components [24, 68]. Most nephrol-
ogists have suggested that reimbursement for 4 treat-
ments per week would be adequate. A mix of patients
with private as well as public insurance and economies
of scale achieved by more than 15 patients in a program
can make a nocturnal hemodialysis program profitable.
One also has to take into account that the decreased ad-
ministration of Epo and intravenous vitamin D analogues
associated with quotidian hemodialysis, depending on the
reimbursement structure, can decrease the profitability of
the dialysis units. The use of a capitated system of reim-
bursement is ideal, as the financial benefits of decreased
hospitalization and lower medication cost will benefit the
provider.
DR. STROM: Would you describe in more detail the
remote monitoring of the patients?
DR. PIERRATOS: All modern hemodialysis machines
have a communication port capable of exporting data to
a computer. The machines can be connected via a modem
and a telephone line or via a computer and an internet
connection to the monitoring center. An internet connec-
tion is preferable, especially if the cost of the overnight
continuous telephone connection is high, as is the case of
long-distance calls. An observer at the center uses com-
mercially available software to monitor all patients on
the same screen. All the information available locally on
the screen of the machine at home is available to the ob-
server at the center, including alarms, pressures, flows,
etc. The function of the observer is to call and awaken
the patient if the alarms persist. The observer can contact
the nurse, technician, or physician on call or dispatch the
police or an ambulance to the home of the patient. Obvi-
ously, conditions that cannot trigger a machine alarm will
not be known to the observer. These include alarms of the
moisture sensors that result from blood or dialysate leaks
or low systemic blood pressure. Blood pressure measure-
ments during the night are disruptive and are avoided. It is
hoped that industry will incorporate the current external
alarms into the machines and develop systems capable of
monitoring the vital signs of the patients, adding value to
the remote monitoring.
DR. RONALD D. PERRONE (Division of Nephrology,
Tufts-New England Medical Center): Do you have any
data on the effect of daily punctures on longevity of the
access? In terms of the patients you discussed, you indi-
cated that these patients are sicker than those receiving
CHD. When I look around our dialysis unit, however, I
can’t imagine the sickest patients being able to perform
this technique at home. Have you looked at the socioe-
conomic status, degree of education, and other variables
for these patients?
DR. PIERRATOS: The issue of the effect of the daily
cannulation of the AV access on its survival is indeed
an important one. Information from retrospective stud-
ies indicates that the diaylsis-access-related problems are
fewer on daily hemodialysis when compared with con-
ventional hemodialysis [15, 69]. Interestingly, a recent
abstract reported an increased number of hospitalization
days for access problems on SDHD [abstract; Carter M
et al, J Am Soc Nephrol 13:619A–620A, 2002]. Therefore
prospective randomized studies are needed to answer this
question. The use of the “buttonhole” technique for AV
fistulas has simplified the teaching and decreased the dif-
ficulty and discomfort of the cannulation [29]. No data
have been published on the outcomes of this technique.
All our home hemodialysis patients have been using this
technique for about 6 years. My impression is that the
access problems are probably fewer on quotidian dialy-
sis, but meticulous attention to the antiseptic technique is
important. Several cases of bacteremia were encountered
using the buttonhole technique.
Regarding your second question, we do not have data
on the socioeconomic status of the patients. Obviously
the patients who are trained for home hemodialysis are
selected because they have the ability and the desire to
be trained; this population is younger by, on average, 10
years than patients undergoing in-center hemodialysis.
As simplified hemodialysis machines are introduced by
industry, it is expected that more patients will become
eligible for training. I would like to stress once more that
although these patients are selected for their ability to be
trained, they are not excluded because of the presence of
comorbidities.
DR. GEETHA NARAYAN (Division of Nephrology, Car-
itas St. Elizabeth’s Medical Center): My question relates to
comparing nocturnal hemodialysis with other modalities
you mentioned. Daily nocturnal hemodialysis seems to be
superior to long intermittent dialysis in Tassin, France,
at least with respect to outcomes such as regression of
LVH. Do you think the difference might be related to
choice of membrane (biocompatible versus cuprophane)
or are there other differences as well, such as the degree
of middle molecule removal? The second comparison is
between daily nocturnal dialysis and SDHD. Although
you did not have much comparative data, I sensed that
the former was better, as evidenced by better phosphorus
control, etc. Is it because of a higher Kt/V? Do you think
the long (nocturnal) dialysis will ultimately prevail?
DR. PIERRATOS: Those are very good questions, and
I am afraid I do not have all the answers. The disadvan-
tages of intermittent hemodialysis as practiced in Tassin
and other centers in comparison with daily nocturnal
hemodialysis include lack of documented regression of
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LVH, worse phosphate control, less-efficient removal of
middle molecules, and imposition of some dietetic re-
strictions. The lack of LVH regression on intermittent
long hemodialysis is rather puzzling in view of the excel-
lent blood pressure control in these patients. Also, there
is no good correlation between the blood pressure de-
crease on daily nocturnal home hemodialysis and regres-
sion of LVH [33]. One wonders whether less extracellular
volume fluctuation is more relevant than blood pressure
control to regression of LVH, as both forms of quotidian
hemodialysis associated with regression of LVH share this
quality. I am not aware of any data correlating the use of
cuprophane membranes or acetate-containing dialysate
to LVH. The lack of use of Epo during the treatment of the
early patient cohorts in Tassin is an interesting possibil-
ity; higher hematocrit has been associated in the preven-
tion of dilated cardiomyopathy [70]. The advantages of
quotidian nocturnal hemodialysis over intermittent noc-
turnal hemodialysis should be weighed against the finan-
cial benefits of the latter. In the present reimbursement
climate, intermittent nocturnal hemodialysis—especially
when performed every other night—represents a very at-
tractive option.
The advantages of long over short daily hemodialy-
sis include higher dialysis dose for both small and larger
molecules, which allows effective dialysis of large patients
and potentially lower middle molecule toxicity, better
phosphate control, better hemodynamic stability, correc-
tion of sleep apnea, ability to use a single-needle system,
unrestricted diet, and the utilization of nighttime for dial-
ysis, allowing the day free for vocational rehabilitation.
The advantages of SDHD are less disturbed sleep, less
concern about safety in relationship to accidental access
disconnection, lower probability of deficiency syndromes,
less exposure to possibly low-quality dialysate, and finally
the ability to perform heparin-free dialysis. Although a
study comparing the two methods was published recently
[59], an adequately powered study would require an un-
realistically large number of patients. The choice of the
method will depend on the dialysis center expertise, spe-
cific patient indications, and the biases of the providers
and the patients.
DR. NARAYAN: So, is the Kt/V higher with the noctur-
nal hemodialysis?
DR. PIERRATOS: Yes, Kt/V is much higher on noctur-
nal hemodialysis than on any other outpatient dialysis
method. The question is whether the increase in Kt/V
provides added benefits. The answer from the HEMO
study pertaining to thrice-weekly dialysis is negative, al-
though it might be different on daily dialysis.
DR. ANDREW S. LEVEY (Division of Nephrology,
Tufts-New England Medical Center): This topic calls out
for a clinical trial to prove the efficacy of DNHD and
demonstrate the magnitude of its benefits. Would you rec-
ommend a feasibility study before moving on to a large-
scale clinical trial? Second, what would be your recom-
mendations for such clinical trials?
DR. PIERRATOS: As you know, such a feasibility study
will be funded by the National Institutes of Health in
collaboration with the Centers for Medicaid and Medi-
care Services. It will be a prospective, randomized, con-
trolled study comparing conventional to both short daily
and quotidian nocturnal hemodialysis; it is expected to be
completed by 2008. I think that the primary end points of
such a study need to include quality-of-life assessment,
effects on cardiovascular disease in the form of control
of hypertension and evidence of regression of LVH, and
effect on hospitalization rates. The effect of quotidian
dialysis on anemia control and nutritional parameters are
often seen after the first 6 to 12 months and might not be
ideal primary end points. At the same time, this study
should collect information on cost, dialysis dose, phos-
phate control, cardiovascular disease, and mortality rates.
This information will be useful for the design of a larger
study. An important aspect of this pilot study is that its
outcome could affect the current dialysis reimbursement
method or rate for quotidian hemodialysis. Some groups
with experience with daily hemodialysis have argued that
the execution of a long study will delay the establishment
of adequate reimbursement for quotidian hemodialysis,
depriving patients with significant comorbidities from the
benefits of the method.
DR. V. BALAKRISHNAN (Division of Nephrology,
Tufts-New England Medical Center): Have you moni-
tored markers of inflammation in these patients?
DR. PIERRATOS: We are monitoring such indices, but
we have not analyzed the data to this point.
DR. BERTRAND L. JABER (Division of Nephrology,
Tufts-New England Medical Center): You have suggested
that the low predialysis b 2-microglobulin levels that you
observed with nocturnal hemodialysis are due to de-
creased generation rather than increased clearance of
this middle molecule. I am intrigued by this possibility
and would like to ask you to speculate on the main deter-
minants of b 2-microglobulin generation.
DR. PIERRATOS: My comment came from the ca-
sual observation that fluctations in the serum level
of b 2-microglobulin in patients undergoing nocturnal
hemodialysis are not explained by changes in the treat-
ment prescription. The main determinant of the elevated
serum level of b 2-microglobulin in patients in ESRD is
the decreased removal by the kidneys. Although dialysis-
related amyloidosis has been linked to dialysis vintage,
the use of bioincompatible membranes, and the presence
of contaminated dialysate [71], little evidence links in-
creased production of b 2-microglobulin with inflamma-
tion [72–74]. Therefore we need more data before we
ascribe lower serum levels of b 2-microglobulin to de-
creased production. The effect of nocturnal hemodialy-
sis on dialysis-related amyloidosis can be more complex.
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Except for the possible beneficial effect by its increased
removal, the reported decreased advanced glycation end
product (AGE) levels on SDHD and nocturnal hemodial-
ysis might be associated with a decreased degree of gly-
cation of b 2-microglobulin [22] [abstract, Cacho C et al,
Perit Dial Int 21:S61, 2002]. Glycation of the molecule
has been linked to increased inflammation at the sites of
deposition, resulting in the clinical syndrome of dialysis-
related amyloidosis [75].
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